AccessibilityHelp
Hutchmed (China) logo

Hutchmed (China)(NASDAQ) HCM

Market Cap$2.49BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)+6%
5 Year-56%
1 Year-5%
1 Month+1%
Premium Feature
Moneyball Superscore
62/100
$14.36
+0.56%
+0.08Today
Hutchmed (China) last closing stock price
MetricPriceDate
Last closeUSD 14.282026-10-22
Hutchmed (China) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.44%USD 13.942026-10-15
1 month+1.49%USD 14.072026-09-22
3 month+29.7%USD 11.012026-07-24
Year to date+7.13%USD 13.332025-12-31
1 year-5.49%USD 15.112025-10-22
3 year-14.64%USD 16.732023-10-23
5 year-55.61%USD 32.172021-10-22
Since inception+5.78%USD 13.502016-03-18

Hutchmed (China) Financials at a Glance

Market Cap

$2.49BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$549.12M

Net Income (TTM)

$17.88M

EPS (TTM)

$0.10

P/E Ratio

140.41

Dividend

$0.00

Beta (Volatility)

1.14 (Average)

Price

$14.36

Volume

23,385.989

Open

$14.36

Previous Close

$14.36

Daily Range

$14.26 - $14.80

52-Week Range

$9.77 - $16.33

Estimated Earnings Date

Mar 4, 2027

HCM News

featured-transcript-logo

Hutchison China MediTech Limited (HCM) Q2 2019 Earnings Call Transcript

Motley Fool TranscriptionJul 30, 2019
Chart going down with man looking

Why Chi-Med Stock Is Tanking Today

Keith SpeightsJun 28, 2019

HCM: Motley Fool Moneyball Superscore

62

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hutchmed (China)

HUTCHMED (China) Limited is a biopharmaceutical firm focused on the discovery, development, and commercialization of innovative targeted and immune-based therapies for various cancers and immune-related disorders. The company operates primarily in oncology and immunology, with a diverse pipeline of promising therapeutic candidates.

Products and Services
  • Developing Savolitinib for non-small cell lung cancer and other cancers
  • Fruquintinib targeting colorectal and gastric cancers
  • Surufatinib for neuroendocrine tumors and solid tumors
Growth Outlook
  • Strong pipeline with multiple candidates in late-stage clinical trials
  • Strategic collaborations with major pharmaceutical companies enhance market reach
  • Increasing demand for innovative cancer therapies in global markets
Financial Highlights
  • Recent quarterly revenue of $139.1 million, showing stable performance
  • Trailing twelve months (TTM) net income margin of 3.26%
  • Current ratio of 5.64 indicates strong liquidity position
HUTCHMED (China) Limited is well-positioned in the biopharmaceutical sector, focusing on oncology and immunology. The company has developed a robust pipeline of innovative therapies, including Savolitinib, Fruquintinib, and Surufatinib, which target various cancer types. The strategic partnerships with leading pharmaceutical companies further bolster its market presence and enhance growth potential. Recent financial performance indicates stability, with a notable revenue figure and a healthy liquidity ratio, reflecting the company's ability to navigate the competitive landscape effectively. As the demand for advanced cancer treatments continues to rise, HUTCHMED's innovative approach and strong pipeline may attract significant investor interest.
AI Generated • Oct 19, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

1,796

CEO

Chig Fung Cheng

Website

www.hutch-med.com

Headquarters

Hong Kong, HK

HCM Financials

Key Financial Metrics (TTM)

Gross Margin

0.20%

Operating Margin

-6.33%

Net Income Margin

3.26%

Return on Equity

1.43%

Return on Capital

-4.10%

Return on Assets

1.03%

Earnings Yield

0.71%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.49BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

174.47M

Volume

23.39K

Avg. Volume

67.56K

Financials (TTM)

Gross Profit

$1.11M

Operating Income

-$34.78M

EBITDA

-$20.52M

Operating Cash Flow

$20.46M

Capital Expenditure

-$10.51M

Free Cash Flow

$9.95M

Cash & ST Invst.

$1.38B

Total Debt

$94.51M

Hutchmed (China) Performance Analysis

Hutchmed (China) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 425,902,33719.4%
20232023-12-31USD 837,270,55596.6%
20242024-12-31USD 630,517,095-24.7%
20252025-12-31USD 549,962,669-12.8%
Hutchmed (China) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-2.5%
Q42025-12-31N/A
Q12026-03-312.8%
Q22026-06-30N/A
Hutchmed (China) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.1373.0%
20232023-12-31USD 0.58N/A
20242024-12-31USD 0.22-62.7%
20252025-12-31USD 2.621113.2%
Hutchmed (China) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-99.6%
Q42025-12-31N/A
Q12026-03-31736.4%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$139.14M

+0.2%

Gross Profit

$23.67M

-57.0%

Gross Margin

17.01%

N/A

Market Cap

$2.49BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.39M

N/A

Employees

1,796

N/A

Net Income

$7.96M

-96.5%

EBITDA

$3.97M

+205.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.38B

+0.8%

Total Debt

$94.51M

-6.2%

Accounts Receivable

$117.56M

-20.0%

Inventory

$40.84M

-15.7%

Long Term Debt

$72.10M

+1.5%

Short Term Debt

$22.41M

-24.6%

Return on Assets

1.03%

N/A

Return on Invested Capital

-2.38%

N/A

Free Cash Flow

$3.30M

+108.0%

Operating Cash Flow

$6.11M

+116.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RCUSArcus Biosciences, Inc.
$18.54-4.24%
ZLABZai Lab Limited
$24.03+9.03%
IDYAIDEAYA Biosciences, Inc.
$34.71-3.90%
AAPGAscentage Pharma Group International
$15.44+3.49%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About HCM

What is the current price of Hutchmed (China)?

Hutchmed (China) is trading at $14.36 per share.

What is the 52-week range for Hutchmed (China)?

Over the past 52 weeks, Hutchmed (China) has traded between $9.77 and $16.33.

How much debt does Hutchmed (China) have?

As of the most recent reporting period, Hutchmed (China) reported total debt of $97.89M.

How much cash does Hutchmed (China) have on hand?

Hutchmed (China) reported $71.33M in cash and cash equivalents in its most recent financial results.

What is Hutchmed (China)’s dividend yield?

Hutchmed (China) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services